Inclusion Criteria:

          1. Patient has a histologically or cytologically confirmed diagnosis of non-squamous
             Non-small cell lung cancer (NSCLC) that is Anaplastic lymphoma kinase (ALK) positive
             as assessed by the Ventana Immunohistochemistry (IHC) test. The test will be performed
             at Novartis designated central laboratories.

          2. Patient has newly diagnosed stage IIIB (who are not a candidate for definitive
             multimodality therapy) or stage IV NSCLC or relapsed locally advanced or metastatic
             NSCLC not previously treated with any systemic anti-cancer therapy (e.g. cytotoxic
             drugs, monoclonal antibody therapy, crizotinib or other ALK inhibitors, or other
             targeted therapies, either experimental or not), with exception of neo-adjuvant or
             adjuvant therapy

          3. Patient has at least one measurable lesion as defined by RECIST 1.1.

        Exclusion Criteria:

          1. Patient with known hypersensitivity to any of the excipients of LDK378
             (microcrystalline cellulose, mannitol, crospovidone, colloidal silicon dioxide and
             magnesium stearate)

          2. Patient with a history of severe hypersensitivity reaction to platinum containing
             drugs, pemetrexed or any known excipients of these drugs.

          3. Patient with symptomatic central nervous system (CNS) metastases who is neurologically
             unstable or has required increasing doses of steroids within the 2 weeks prior to
             screening to manage CNS symptoms.